TGFB1 and Myocardial fibrosis: PAP-3.2KD treatment protects ADR-induced pathological changes, and inhibits ADR-induced myocardial fibrosis and myocardial apoptosis through the inhibition of TGF-β/SMAD pathway, suggesting that PAP-3.2KD may be one potential protective drug during cancer treatment of ADR.